Fortis Technologies has produced an application note on the ability to separate metabolites within high-performance liquid chromatography (HPLC) with its Diphenyl stationary phase.
Metabolites within HPLC probably cause the most problems along with polar analytes in terms of the ability to separate and resolve them from either the parent ion or each other.
Subtle changes in a functional group or the position of a functional group, loss or gain in an atom or functional group can all be difficult for traditional C18 chemistries to differentiate.
Fortis Technologies' application note focuses on the ability to separate these metabolites from each other and/or the parent compound in a simple way with the company's Diphenyl stationary phase.
Producing three mechanisms for analytes to interact with including a large steric term helps gain the much-needed selectivity so often missing.
Available as a 1.7um particle for use in UHPLC for ultimate sensitivity, or as an analytical and prep particle, Fortis Diphenyl offers an uncomplicated method of analysis for metabolites leaving the ability to run 'generic screens' still intact.
Mark Woodruff, director of sales and marketing at Fortis Technologies, said: 'Around 20-30 per cent of compounds cause the analyst problems that are difficult to fulfil on a C18 column, Fortis Diphenyl offers a vastly alternative selectivity in order to try and achieve suitable resolution without a major method development effort, leaving the analysts to concentrate on the important goal, the result.'
